NKCL Bio Group Inc. (NKCL) has announced that it had signed a 3-party MOU with PnB Group and MK Lab for distribution in the Philippines.

PnB Group is a blockchain-based IT company, leading the Philippine market in fintech and IT solutions, and MK Lab is a company that operates K-beauty business in the Philippines under the slogan "Place for All K-Beauty".

Based on NKCL's cell culture technology, PnB Group and MK Lab's business experience and capabilities in the Philippines, this MOU promotes the development of various products and services through mutual cooperation among the parties, and gives priority to each other in the future in specific businesses. The purpose is to create independent business opportunities through designation of mutually preferred negotiators, etc.

In addition, based on NKCL's original cell culture technology, it will promote the creation of markets related to NK cells, immune care, and anti-aging programs in the Philippines.

In addition, through this cooperation, the two companies plan to start distributing medical devices and products using the existing distribution network established in the Philippines within this year. By the long perspective in the Philippine cancer treatment market, we plan to promote the certification of NK cell therapy by the Philippine FDA. NKCL's products and services will be distributed by a one-stop cooperative model for licensing, distribution channel discovery, and network business in the Philippines.

According to World Health Organization (WHO) data released in 2020, more than 6 million Filipinos have been diagnosed with diabetes, and the number of diabetics in the Philippines is expected to reach 7.7 million by 2030. The prevalence of diabetes in the Philippines (ages 20-79) is 7.1% in 2021, making it the fourth leading cause of death in the country.

In addition, during the lockdown period due to COVID-19 in the Philippines, vitamin searches and sales surged, and the importance of preventing COVID-19 and enhancing immunity was raised.

NK cell therapy, being researched and developed by NKCL Bio Group, is not only a very effective treatment for the removal of abnormal cells such as cancer, many studies are conducted as it has been found to be effective in the treatment and symptom relief of diabetes as well.

Accordingly, an NKCL official expressed willingness saying, “We will consider the opinions derived from this agreement as a major strategy for future business and proceed with the local business without any setbacks.”